Company News: Page (1) of 1 - 08/05/14 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

NOVADAQ Reports Second Quarter 2014 Financial Results

(August 05, 2014)

TORONTO, Aug. 5, 2014 (GLOBE NEWSWIRE) -- Novadaq® Technologies Inc. ("NOVADAQ" or the "Company") (Nasdaq:NVDQ) (TSX:NDQ), the leading developer and provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, today announced financial results for its second quarter ended June 30, 2014. Unless otherwise indicated, all dollar amounts in this press release are expressed in United States ("U.S.") dollars.



NOVADAQ reported second quarter 2014 revenues of $11.2 million, compared to $8.1 million in the second quarter of 2013, representing an increase of 38%. NOVADAQ's strategy of investing in a direct sales team resulted in $5.1 million in PINPOINT® and LUNA® sales compared to $1.2 million in the second quarter of last year. During the second quarter, royalty revenues were recognized only from da Vinci® Si systems, while royalty revenues from the new da Vinci Xi systems are delayed until U.S. Food and Drug Administration clearance is received.



NOVADAQ estimates that procedures performed using SPY® technology systems during the quarter was 7,400, representing an increase of 39%, year-over-year and an increase of 13% over the previous quarter. The increase was mainly driven by PINPOINT, LUNA and FIREFLY™.


Second quarter gross profits of $6.9 million (62% margin), represented an increase of 37% compared to profits of $5.1 million (62% margin) in the same period last year.




Net income of $6.3 million for the second quarter of 2014 increased by $16.0 million compared with the $9.7 million net loss in second quarter of 2013. Second quarter 2014 earnings per share were $0.11, excluding the impact of a non-cash $10.8 million warrants revaluation gain in the period, the loss per share was $0.08.



Second quarter 2014 operating burn (cash consumed by operating activities before changes in working capital) was $1.5 million compared to an operating burn of $0.6 million in the second quarter of 2013. This difference in operating burn was mainly driven by increased sales and distribution expenses associated with the build-out of NOVADAQ's direct sales and marketing infrastructure. During the period, working capital consumed was $5.7 million, and $1.8 million was invested in fixed assets, including $1.7 million used to build SPY technology systems for evaluation and placement. The Company also utilized $6.7 million in cash, inclusive of transaction costs, to complete the acquisition of Aïmago SA business.



Cash and cash equivalents were $162.1 million at June 30, 2014, reflecting a decrease of $15.1 million, compared to the cash position as at March 31, 2014.



During the second quarter, 129 SPY technology systems, including FIREFLY, were shipped globally. Included in those shipments were sales of 47 PINPOINT, LUNA and SPY systems. Exiting the quarter, more than 100 PINPOINT and LUNA systems were installed as evaluation units.



"The second quarter marks a milestone for us, as approximately half of our revenues were generated from direct sales," commented Dr. Arun Menawat, NOVADAQ President and CEO. "In line with the clinical value proposition of our products, we are announcing the initiation of two multi-center studies using PINPOINT: PILLARTM III, focused on lower anterior colon resection and the FILMTM study for lymphatic mapping in gynecological oncology."



Conference Call Details



NOVADAQ is pleased to invite all interested parties to participate in a conference call, on August 5, 2014 at 8:30 a.m. Eastern Time, during which the results will be discussed.



Those wishing to access the live conference call by telephone should dial 1-877-407-8031 (Canada and the United States) or 1-201-689-8031 (International) several minutes prior to the beginning of the call.



A replay of the conference call can be accessed by dialing 1-877-660-6853 (Canada and the United States) or 1-201-612-7415 (International) and entering the conference identification number 13587138 when prompted.



The call will also be archived for 90 days on the Company's website at novadaq.com under the "Events" tab in the Investor's section. A replay of the call will be available for download to a portable audio player or computer, as an MP3 or podcast file, at the same location on NOVADAQ's website.



About Novadaq Technologies Inc.



Enabling medical professionals with clinically relevant, point-of-care imaging solutions to enhance the lives of patients and their caregivers, while reducing health care costs, is NOVADAQ®'s global mission. SPY® fluorescence imaging technology provides surgeons with real-time visualization, leading to improved outcomes and reduced costs without exposing the patient to radiation. More than 100 peer-reviewed publications demonstrate that the use of SPY imaging technologies during complex surgery and diagnostic procedures, leads to lower rates of post-operative complications and lower hospital costs.



SPY Imaging Systems are United States Food and Drug Administration 510(k) cleared for use in seven surgical specialties. The endoscopic version of SPY called PINPOINT®, combines the capabilities of SPY Imaging with high definition ("HD") visible light visualization offered by conventional endoscopes. LUNA® is used to assess perfusion in patients being treated for non-healing wounds.



Forward Looking Statements



Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on NOVADAQ's current beliefs as well as assumptions made by and information currently available to NOVADAQ and relate to, among other things, the Company's strategy, strategic goals, research and development activities, research and clinical testing outcomes, taxes, capital expenditures, future operations, future financial position, future revenues/results, projected costs, prospects and plans and objectives of management.



Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by NOVADAQ in its public securities filings available at www.sec.gov and www.sedar.com, actual events may differ materially from current expectations. NOVADAQ disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.






























































































































































































































Novadaq Technologies Inc.

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

 

(Unaudited)

(expressed in U.S. dollars, except common shares outstanding)

 

 

As at

June 30, 2014

As at

December 31, 2013

ASSETS

 

 

Current assets

 

 

Cash and cash equivalents

$162,053,197

$182,329,782

Accounts receivable

12,799,028

8,502,095

Prepaid expenses and other assets

1,648,767

1,032,431

Inventories

4,742,937

3,845,695

 

181,243,929

195,710,003

Non-current assets

 

 

Property and equipment, net

14,927,303

13,360,833

Intangible assets, net

12,895,360

3,303,647

 

 

 

Total Assets

$209,066,592

$212,374,483

 

 

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

Current liabilities

 

 

Accounts payable and accrued liabilities                     

$5,880,512

$7,123,563

Provisions

257,705

187,080

Deferred revenue

385,340

380,325

Deferred partnership fee revenue

1,300,000

1,300,000

Repayable government assistance


17,587

 

7,823,557

9,008,555

Non-current liabilities

 

 

Deferred revenue

179,084

193,626

Deferred partnership fee revenue

1,341,666

1,991,666

Shareholder warrants

25,186,805

26,065,994

 

 

 

Total Liabilities

$34,531,112

$37,259,841

 

 

 

Shareholders' Equity

 

 

Share capital

$314,763,726

$307,103,074

Contributed surplus

10,543,578

8,953,041

Deficit

(150,771,824)

(140,941,473)

 

 

 

Total Shareholders' Equity

$174,535,480

$175,114,642

 

 

 

Total Liabilities and Shareholders' Equity

$209,066,592

$212,374,483

 

 

 

Common shares outstanding

55,474,068

54,894,038


































































































































































































































 

 

Novadaq Technologies Inc.

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)

 

(Unaudited)

(expressed in U.S. dollars)

 

 

For the three months ended

For the six months ended

 

June 30, 2014

June 30, 2013

June 30, 2014

June 30, 2013

 

 

 

 

 

Product sales

$10,391,137

$7,075,710

$19,782,528

$13,375,953

Royalty revenue

270,000

467,766

675,000

908,444

Partnership fee revenue

325,000

325,000

650,000

650,000

Service revenue

166,019

229,473

342,850

441,995

Total revenues

11,152,156

8,097,949

21,450,378

15,376,392

Cost of sales

4,232,023

3,043,252

7,833,920

5,775,394

Gross profit

6,920,133

5,054,697

13,616,458

9,600,998

 

 

 

 

 

Selling and distribution costs

7,192,559

3,512,448

13,900,119

5,860,704

Research and development expenses

2,331,027

2,045,826

4,585,945

3,533,024

Administrative expenses

1,968,860

1,742,733

3,963,471

3,103,472

Write-down of inventory


31,285


31,285

Total operating expenses

11,492,446

7,332,292

22,449,535

12,528,485

 

 

 

 

 

Loss from operations

(4,572,313)

(2,277,595)

(8,833,077)

(2,927,487)

 

 

 

 

 

Finance costs


(5,300)


(176,489)

Finance income

59,088

17,861

127,468

32,704

Warrants revaluation adjustment

10,794,176

(7,472,882)

(1,149,742)

(9,578,924)

Gain on investment


25,000

25,000

25,000

Income (loss) before income taxes

6,280,951

(9,712,916)

(9,830,351)

(12,625,196)

Income tax expense


(25,000)


(45,000)

Net income (loss) and comprehensive income (loss) for the period

$6,280,951

($9,737,916)

($9,830,351)

($12,670,196)

Basic income (loss) and comprehensive income (loss) per share for the period

$0.11

($0.21)

($0.18)

($0.29)

Diluted income (loss) and comprehensive income (loss) per share for the period

($0.08)

($0.21)

($0.18)

($0.29)


















































































































































































































































































































































 

 

Novadaq Technologies Inc.

 

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

 

(Unaudited)

(expressed in U.S. dollars)

 

 

For the three months ended

For the six months ended

 

June 30, 2014

June 30, 2013

June 30, 2014

June 30, 2013

OPERATING ACTIVITIES

 

 

 

 

Net Income (loss) and comprehensive income (loss) for the period

$6,280,951

($9,737,916)

($9,830,351)

($12,670,196)

Items not affecting cash

 

 

 

 

Depreciation of property and equipment

1,248,889

808,894

2,401,441

1,529,829

Amortization of intangible assets

188,716

55,586

277,040

170,495

Stock-based compensation

1,554,107

816,858

2,330,178

1,216,695

Imputed interest on convertible debentures


2,073


169,056

Loss (gain) on investment

 

(25,000)

(25,000)

(25,000)

Warrants revaluation adjustment

(10,794,176)

7,472,882

1,149,742

9,578,924

Write-down of inventory


31,285


31,285

 

(1,521,513)

(575,338)

(3,696,950)

1,088

Changes in non-cash working capital

 

 

 

 

Increase in accounts receivable

(3,689,277)

(1,748,098)

(4,296,933)

(2,736,679)

Increase in inventories

(1,140,867)

(944,171)

(897,242)

(1,652,160)

Increase in prepaid expenses and other assets

(907,222)

(689,167)

(616,336)

(389,491)

Decrease in accounts payable and accrued liabilities and provisions

(25,759)

984,821

(1,172,126)

1,341,646

Increase (decrease) increase in deferred revenue and deferred partnership revenue

35,999

(220,002)

5,015

(221,783)

Net change in non-cash working capital balances related to operations

(5,727,126)

(2,616,617)

(6,977,622)

(3,658,467)

 

 

 

 

 

Decrease in long term deferred revenue and deferred partnership revenue

(365,725)

(319,589)

(664,542)

(611,433)

Cash used in operating activities

(7,614,364)

(3,511,544)

(11,339,114)

(4,268,812)

 

 

 

 

 

INVESTING ACTIVITIES

 

 

 

 

Purchase of property and equipment

(2,025,681)

(1,886,301)

(4,316,388)

(3,138,217)

Disposals of property and equipment

263,697

127,652

348,477

155,422

Purchase of intangible assets including transaction costs

(6,368,753)


(6,368,753)


Redemption of investments


25,000

25,000

25,000

Cash used in investing activities

(8,130,737)

(1,733,649)

(10,311,664)

(2,957,795)

 

 

 

 

 

FINANCING ACTIVITIES

 

 

 

 

Proceeds from issuance of common shares


57,856,500


57,856,500

Transaction costs paid relating to issuance of common shares


(3,181,570)


(3,181,570)

Repayment of government assistance


(53,504)

(17,587)

(107,665)

Proceeds from exercise of options

355,414

1,562,915

1,107,804

1,612,117

Proceeds from exercise of warrants

284,276

368,281

284,276

621,912

Cash provided by financing activities

639,690

56,552,622

1,374,493

56,801,294

 

 

 

 

 

Net (decrease) increase in cash and cash equivalents

(15,105,411)

51,307,429

(20,276,285)

49,574,687

Impact of foreign exchange on cash and cash equivalents

2,034

(6,716)

(300)

(8,288)

Cash and cash equivalents at beginning of period

177,156,574

37,219,867

182,329,782

38,954,181

 

 

 

 

 

Cash and cash equivalents at end of period

$162,053,197

$88,520,580

$162,053,197

$88,520,580

CONTACT: Novadaq Technologies Inc.
Elif McDonald
Vice President, Corporate Communications and
Investor Relations
1-905-629-3822 ext: 218
investor@novadaq.com
www.novadaq.com

Stephen Kilmer
Investor Relations
1-647-872-4849
skilmer@novadaq.com



Novadaq logo


Page: 1


Related Keywords: MEDICAL, EARNINGS, CONFERENCE CALLUSA, Inc., Medicine, Surgery, healthcare, Surgery, Science, Medical, Business, Other,

HOT THREADS on DMN Forums

@ Copyright, 2014 Digital Media Online, All Rights Reserved